The historical rank and industry rank for Novonesis (Novozymes) B's ROE % or its related term are showing as below:
MEX:NSISN'
s ROE % Range Over the Past 10 Years
Min: 4.69 Med: 26.65 Max: 28.63
Current: 5.48
During the past 13 years, Novonesis (Novozymes) B's highest ROE % was 28.63%. The lowest was 4.69%. And the median was 26.65%.
MEX:NSISN's ROE % is ranked better than 51.19% of 1590
companies
in the Chemicals industry
Industry Median: 5.195
vs MEX:NSISN: 5.48
Novonesis (Novozymes) B (MEX:NSISN) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novonesis (Novozymes) B ROE % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's ROE % distribution charts can be found below:
* The bar in red indicates where Novonesis (Novozymes) B's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Novonesis (Novozymes) B (MEX:NSISN) has a ROE % of 7.27% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Novonesis (Novozymes) B and its competitors. This is 73% below median its historical median of 26.65. Over the past decade, Novonesis (Novozymes) B's ROE % has ranged from 4.69 to 28.63. According to the industry distribution chart, Novonesis (Novozymes) B ranks #776 out of 1590 companies in the Chemicals industry, placing it in the top 48.8%.
Is Novonesis (Novozymes) B's ROE % too high?
Novonesis (Novozymes) B's current ROE % of 7.27% is 73% below median its 10-year median of 26.65. Over the past 10 years, this metric has ranged from a low of 4.69 to a high of 28.63. The Chemicals industry median ROE % is 5.20. Novonesis (Novozymes) B's value of 7.27% is 39.9% above this industry median. Based on the distribution chart, Novonesis (Novozymes) B ranks #776 out of 1590 companies in the Chemicals industry, which is above the industry midpoint. Overall, Novonesis (Novozymes) B has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's ROE % compare to LIN and SHW?
According to the Chemicals industry distribution chart, Novonesis (Novozymes) B ranks #776 out of 1590 companies for ROE %. This puts Novonesis (Novozymes) B in the upper half of its industry. The industry median ROE % is 5.20. Novonesis (Novozymes) B's value of 7.27% is 39.9% above this benchmark. Historically, Novonesis (Novozymes) B's own ROE % has ranged from 4.69 to 28.63 over the past decade. While the company's 10-year median is 26.65 vs. the industry median of 5.20, Novonesis (Novozymes) B has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Chemicals company?
The median ROE % among Chemicals companies is 5.20, based on 1,590 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novonesis (Novozymes) B's current ROE % of 7.27% is 39.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Novonesis (Novozymes) B and its competitors. For the Chemicals industry, the median ROE % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novonesis (Novozymes) B's current ROE % is 7.27%, which is 73% below median its own 10-year median of 26.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Novonesis (Novozymes) B (MEX:NSISN) has a current ROE % of 7.27%. The stock's GF Value™ is MXN979.45, compared to a current price of MXN911.11 — trading 7% below its estimated fair value. The current ROE % is 7.27%, which is 73% below median its 10-year median of 26.65 and 39.9% above the Chemicals industry median of 5.20. Novonesis (Novozymes) B's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Novonesis (Novozymes) B (MEX:NSISN), the current ROE % is 7.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novonesis (Novozymes) B (MEX:NSISN) Overvalued in 2026?
Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be undervalued.
The current stock price of MXN911.11 is trading 7% below its estimated GF Value™ of MXN979.45.
Key valuation signals for MEX:NSISN:
ROE %: 7.27% (73% below median its 10-year median of 26.65)
GF Value™: MXN979.45 vs. price of MXN911.11 (7% below fair value)
Industry Position: 39.9% above the Chemicals median (#776 of 1590)
No single metric tells the full story. See the MEX:NSISN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
91GF Score
Get the complete analysis for MEX:NSISN
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NSISN has been successfully added to your 
